Is Ultragenyx Pharmaceutical (RARE) One of the Best Biotech Stocks to Buy According to Wall Street Analysts?

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is one of the champion biotech stocks to bargain according to Wall Street analysts. On December 4, Citi expert Yigal Nochomovitz reiterated a Buy standing connected Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) and acceptable a $103 terms target. The affirmative stance aligns with a Consensus Strong Buy standing from 13 Wall Street analysts, comprising 12 Buys and 1 Hold.

The mean terms people connected Ultragenyx Pharmaceutical is $76.83, implying 111.65% upside imaginable from existent levels of $36.30. On November 21, Cantor Fitzgerald reaffirmed its Overweight standing and $105 terms people connected Ultragenyx Pharmaceutical pursuing third-quarter 2025 results and caller fiscal actions. Ultragenyx, which focuses connected uncommon and ultra-rare familial diseases, announced connected November 4 the merchantability of an further information of aboriginal royalty involvement successful Crysvita, 1 of its cardinal commercialized products. Cantor noted that portion the woody strengthens liquidity, it does not change the firm’s wide valuation presumption of the company.

Ultragenyx reported Q3 gross of $160 million, beneath the statement of $167 million, and EPS of -1.81 versus the expected -1.23. Despite the shortfalls, the institution confirmed its full-year gross guidance of $640 to $670 million. To further enactment its fiscal position, Ultragenyx sold 25% of its North American Crysvita economics, receiving $400 cardinal upfront from OMERS. Cantor Fitzgerald adjusted its exemplary to relationship for these moves but maintained assurance successful Ultragenyx’s semipermanent growth, highlighting the company’s strategical absorption connected uncommon illness therapies and its quality to usage Crysvita royalties to beforehand the pipeline and make shareholder value.

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is simply a biopharmaceutical institution focused connected processing and commercializing treatments for severe, debilitating, rare, and ultra-rare familial diseases, utilizing modalities similar biologics, cistron therapies, and ASOs to code precocious unmet aesculapian needs.

While we admit the imaginable of RARE arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 12 Best Consumer Goods Stocks Billionaires Are Quietly Buying and Goldman Sachs Penny Stocks: Top 12 Stock Picks.

Disclosure: None. This nonfiction is primitively published at Insider Monkey.